Vertex's new drugs are gaining momentum as Alyftrek tops $1 billion in sales and Journavx prescriptions accelerate.
Vertex tops Q1 estimates as revenues climb 8% on strong CF drug demand and new product gains. Its pipeline has advanced and its 2026 guidance reaffirmed.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK ® (vanzacaftor ...
Over the past three decades, meaningful progress has been made in the research and understanding of cystic fibrosis (CF). 1 ...
Moby Strategic Execution and Portfolio Diversification. Management attributes Q1 performance to strong executio ...
May 4 (Reuters) - Vertex Pharmaceuticals on Monday beat Wall Street estimates for first-quarter adjusted profit, helped by a ...
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) ranks among the most profitable biotech stocks to buy now. On April 13, ...
Over the 3 months period, Vertex Pharmaceuticals showcased positive performance, achieving a revenue growth rate of 9.5 ...
Vertex Pharma has said it will use a priority review voucher (PRV) to speed up the FDA review of its new once-daily triple therapy for cystic fibrosis, which has just hit all its objectives in a pair ...
CNW/ - The TELUS Health 2026 Drug Data Trends & National Benchmarks Report, released today at the TELUS Health Annual ...
By Leslie Herod Since its inception, Colorado’s Prescription Drug Affordability Board (PDAB) created fear among patients ...
By Leslie Herod Since its inception, Colorado’s Prescription Drug Affordability Board (PDAB) created fear among patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results